See more : Jack Creek Investment Corp. (JCIC) Income Statement Analysis – Financial Results
Complete financial analysis of Achieve Life Sciences, Inc. (ACHV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Achieve Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Reading International, Inc. (RDIB) Income Statement Analysis – Financial Results
- Financial Products Group Co., Ltd. (7148.T) Income Statement Analysis – Financial Results
- Prudential Financial, Inc. 5.62 (PRS) Income Statement Analysis – Financial Results
- Guangdong Fuxin Technology Co., Ltd. (688662.SS) Income Statement Analysis – Financial Results
- Indian Energy Exchange Limited (IEX.NS) Income Statement Analysis – Financial Results
Achieve Life Sciences, Inc. (ACHV)
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 8.75M | 408.41K | 12.10M | 5.10M | 18.90M | 16.60M | 4.50M | 1.10M |
| Cost of Revenue | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.22M | 3.69M | -600.00K | -800.00K | -600.00K | -500.00K | -300.00K | 5.50M |
| Gross Profit | -228.00K | -236.00K | -250.00K | -255.00K | -254.00K | -282.00K | -282.00K | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 3.53M | -3.28M | 12.70M | 5.90M | 19.50M | 17.10M | 4.80M | -4.40M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.33% | -803.51% | 104.96% | 115.69% | 103.17% | 103.01% | 106.67% | -400.00% |
| Research & Development | 15.81M | 30.08M | 23.97M | 6.88M | 9.67M | 5.87M | 3.10M | 14.79M | 25.11M | 46.22M | 55.32M | 39.95M | 21.55M | 18.48M | 24.16M | 7.82M | 27.15M | 41.10M | 24.49M | 10.71M | 7.65M | 8.96M | 5.22M | 3.26M | 5.60M | 10.50M | 11.60M | 11.20M | 7.20M | 0.00 |
| General & Administrative | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 0.00 | 5.84M | 3.96M | 3.29M | 8.22B | 7.58B | 5.57B | 5.87B | 3.01B | 3.24B | 3.31M | 3.95M | 5.78M | 6.55M | 7.20M | 3.81M | 2.20M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.21B | -7.57B | -5.56B | -5.86B | -3.01B | -3.24B | 888.00 | 432.52K | 720.00K | -50.00K | 0.00 | -10.00K | 0.00 | 0.00 |
| SG&A | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 6.23M | 5.84M | 3.96M | 3.29M | 8.22M | 7.58M | 5.57M | 5.87M | 3.01M | 3.24M | 3.31M | 4.38M | 6.50M | 6.50M | 7.20M | 3.80M | 2.20M | 3.50M |
| Other Expenses | 0.00 | -1.55M | -58.00K | -49.00K | 133.00K | 126.00K | 165.00K | 1.06M | 1.95M | 3.23M | 120.00K | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| Operating Expenses | 27.02M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.70M | 17.80M | 19.40M | 15.50M | 9.80M | 3.80M |
| Cost & Expenses | 27.25M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.10M | 17.00M | 18.80M | 15.00M | 9.50M | 9.30M |
| Interest Income | 825.00K | 199.00K | 17.00K | 69.00K | 170.00K | 171.00K | 21.00K | 203.00K | 119.00K | 35.00K | 150.00K | 292.00K | 220.00K | 86.00K | 47.00K | 210.00K | 2.30M | 2.85M | 714.87K | 289.59K | 213.19K | 468.48K | 539.69K | 692.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.85M | 1.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 531.00K | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 | 434.00 | 2.98K | 6.82K | 24.63K | 42.14K | 31.67K | 13.86K | 34.06K | 470.00K | 200.00K | 970.00K | 200.00K | 800.00K | 600.00K |
| Depreciation & Amortization | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 188.00K | 244.00K | 223.00K | 227.00K | 100.00K | 75.00K | 52.00K | 50.00K | 89.00K | 655.69K | 609.62K | 586.16K | 515.48K | 380.43K | 580.62K | 258.10K | 357.54K | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| EBITDA | -26.73M | -40.33M | -32.90M | -14.48M | -16.14M | -12.41M | -13.35M | -19.94M | -16.56M | -26.02M | -31.62M | -21.00M | -22.21M | -15.53M | 1.42M | -10.60M | -12.41M | -22.94M | -20.50M | -15.73M | -10.26M | -11.59M | 474.45K | -6.88M | 589.54K | -11.08M | 700.00K | 2.10M | -4.60M | -7.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -318.57% | -103.27% | -110.64% | -128.20% | -167.50% | -538.68% | -41.80% | -10.57% | -55.80% | -71.80% | -114.17% | -257.16% | -6.06% | -41,030.90% | -46,373.91% | 5.42% | -2,724.05% | 12.40% | -237.25% | -2.12% | 7.83% | -108.89% | -727.27% |
| Operating Income | -27.25M | -40.80M | -33.09M | -14.75M | -16.53M | -12.81M | -6.63M | -21.19M | -18.75M | -29.47M | -35.33M | -25.99M | -22.29M | -14.75M | -2.47M | -6.26M | -15.23M | -26.29M | -21.81M | -16.58M | -10.64M | -12.17M | 216.35K | -7.23M | 900.00K | -11.90M | 100.00K | 1.60M | -5.00M | -8.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -418.65% | -103.27% | -108.67% | -118.22% | -129.32% | -405.51% | -108.29% | -9.65% | -31.11% | -75.68% | -117.39% | -264.21% | -6.26% | -42,552.60% | -48,696.39% | 2.47% | -1,770.96% | 7.44% | -233.33% | 0.53% | 9.64% | -111.11% | -745.45% |
| Total Other Income/Expenses | -2.57M | -1.55M | -58.00K | 20.00K | 133.00K | 126.00K | -7.00M | -1.47M | 1.95M | 3.49M | 3.48M | 6.55M | 7.61M | -4.88M | 117.00K | 421.00K | 2.17M | 2.74M | 712.20K | -735.04K | 171.05K | 436.81K | 525.83K | 4.91M | 440.46K | 711.22K | 1.00M | 600.00K | -400.00K | -500.00K |
| Income Before Tax | -29.82M | -42.35M | -33.15M | -14.73M | -16.40M | -12.69M | -13.63M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -15.58M | 2.47M | -10.69M | -15.36M | -26.40M | -21.81M | -16.31M | -10.47M | -11.74M | 742.18K | -2.32M | 430.00K | -11.17M | 1.10M | 2.20M | -5.40M | -8.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -114.45% | 9.65% | -53.11% | -76.30% | -117.90% | -264.16% | -6.16% | -41,868.40% | -46,949.14% | 8.48% | -569.13% | 3.55% | -219.02% | 5.82% | 13.25% | -120.00% | -790.91% |
| Income Tax Expense | 0.00 | -475.00K | -250.00K | -69.00K | -254.00K | -126.00K | -3.05M | -1.06M | -1.95M | -3.49M | -3.48M | -6.55M | -7.61M | -3.00M | -3.01M | -2.06M | -2.17M | -2.74M | -712.20K | -264.96K | -171.05K | -101.48K | 200.00K | -176.94K | 470.00K | -730.00K | 100.00K | 500.00K | 500.00K | 200.00K |
| Net Income | -29.82M | -41.88M | -32.90M | -14.66M | -16.14M | -12.69M | -10.58M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -12.58M | 5.48M | -4.20M | -13.06M | -23.55M | -21.10M | -16.31M | -10.47M | -11.64M | 542.18K | -2.15M | 400.00K | -11.20M | 1.00M | 1.70M | -5.90M | -8.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -92.42% | 21.44% | -20.88% | -64.89% | -105.18% | -255.58% | -6.16% | -41,868.40% | -46,543.20% | 6.20% | -525.81% | 3.31% | -219.61% | 5.29% | 10.24% | -131.11% | -809.09% |
| EPS | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.48K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| EPS Diluted | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.47K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| Weighted Avg Shares Out | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.61K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
| Weighted Avg Shares Out (Dil) | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.65K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
Designation is based on results from the Phase 2 ORCA-V1 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes compared with placebo Designation is based on results from the Phase 2 ORCA-V1 trial that showed...
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
SEATTLE and VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it...
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
SEATTLE and VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will...
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve...
Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA that successful completion of ORCA-OL trial is necessary for NDA filing of...
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from...
Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan...
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will...
Source: https://incomestatements.info
Category: Stock Reports